Trials / Completed
CompletedNCT00401635
END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin
Phase II Multicentered Study of First-Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With the Combination of Carboplatin and Liposomal Doxorubicin
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 42 (planned)
- Sponsor
- National Cancer Institute, Naples · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate activity and toxicity of the combination of carboplatin and liposomal doxorubicin as first-line chemotherapy of patients with advanced or recurrent endometrial carcinoma.
Detailed description
Treatment is planned with carboplatin AUC 5 given IV on day 1 and liposomal doxorubicin 40 mg/m2 given IV on day 1, with treatment repeated every 28 days. Delays in treatment administration and dose reductions have been planned according to toxicity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | liposomal doxorubicin | |
| DRUG | carboplatin |
Timeline
- Start date
- 2002-11-01
- First posted
- 2006-11-20
- Last updated
- 2007-09-05
Locations
4 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT00401635. Inclusion in this directory is not an endorsement.